# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jefferies analyst Glen Santangelo upgrades Collegium Pharmaceutical (NASDAQ:COLL) from Hold to Buy and raises the price targ...
Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving th...
Needham analyst Serge Belanger downgrades Collegium Pharmaceutical (NASDAQ:COLL) from Buy to Hold.
Piper Sandler analyst David Amsellem downgrades Collegium Pharmaceutical (NASDAQ:COLL) from Overweight to Neutral and mainta...
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.45 per share which beat the analyst consensus estimate...